Centered on amniotic fluid stem cells (AFSCs) and exosomes, U-NEURONhasbuilt a regenerative medicine drug development platform focused on neural repair and tissue regeneration. Targeting major unmet medical needs that conventional treatments cannot resolve, the platform pioneers innovative therapeutic mechanisms.

This platform will serve as the company’s key growth engine toward achieving NT$10 billion in revenue.

Core R&D Pipeline

UA002 | Erectile Dysfunction (ED)

New Drug Development Platform - 永立榮生醫

Promotes neural and vascular regeneration and repair using amniotic fluid stem cells

  • Overcomes the limitations of conventional symptomatic treatments
  • Rebuilds corpus cavernosum nerve and vascular networks

Restores natural physiological function rather than providing temporary stimulation👉 Specially targets:

  • • Patients with nerve damage following prostate surgery
  • • Complex neurovascular damage caused by diabetes
  • • Non-responders to traditional PDE-5 inhibitors (up to 30–50%)
UB003 | Dry Eye Disease / Neurotrophic Keratitis

New Drug Development Platform - 永立榮生醫

Exosome-directed ophthalmic regenerative therapy

  • Promotes corneal nerve repair
  • Alleviates chronic inflammation and dry eye symptoms
  • Targets rare diseases and refractory patients

Current Status:

  • CMC / Preclinical / Pre-IND (PIND) Preparation
  • Demonstrated a favorable safety profile and positive efficacysignals
New Drug Development Platform - 永立榮生醫
Core Technical Advantages

Unlike conventional treatments that provide only short-term effects:

Comparison Item
Conventional Treatment (e.g. Viagra)
UA002 (Amniotic Fluid Stem Cell Platform)
Core Mechanism
Vasodilation (symptomatic relief)
Neural + Vascular Regeneration (root-cause repair)
Administration Method
Requires daily / prior-use dosing
Long-lasting effect from single treatment
Physiological Significance
Potential side effects
Core mechanism based on cellular repair
Clinical Trial & Research Partner Institutions

International Clinical and Academic Team

This platform is co-led by top global experts in urology and regenerative medicine:

  • Authority in molecular urology at UCSF
  • Key scientist team involved in discovering the physiological mechanism of Viagra
  • Principal Investigator for Taiwan clinical trials (Phase 1/2a)
  • Chief Editor of international journals and president-level expert of academic societies

Clinical and Regulatory Progress

UA002 Clinical Development Roadmap

 

2024 2025 – 2026 2027
Phase 1 Completion (Safety Established)
TFDA & CDE Dual-Track ExpeditedRegulatory Guidance
Phase 2b

Double-Blind Trial (Efficacy Validation)

👉Policy Support
👉 Accelerated Review Advantage
👉 High Success Potential

Market Potential & Commercial Value

Erectile Dysfunction (ED) Market

Global Market

Approximately USD 6.7 Billion (continuing to grow)

Taiwan Male Population Aged 40+

Approximately 6.6 Million

Potential ED Population

Approximately 1.7 Million

Target Audience & Market Potential

New Drug Development Platform - 永立榮生醫

• Mid-to-High Net-Worth Males

High purchasing power and strong willingness to seek advanced treatments

New Drug Development Platform - 永立榮生醫

• Chronic Disease Patients (Diabetes / Post-Surgical)

High medical necessity for neurovascular repair and regenerative solutions

Core Value Focus:
Targeting patient populations with limited benefit from conventional therapies to capture a high-growth, underserved market segment.

New Drug Development Platform - 永立榮生醫

Contact Us